CancerAGORANCT07041710
Rehabilitation of Taste and Smell Disorders Associated With Chemotherapy Using Aromatherapy
A study testing experimental in day hospital and taste and smell disorders questionnaire in people with Cancer, run by Médipôle Lyon-Villeurbanne at 1 site in France.
Trial summary
Changes in taste and smell can occur during chemotherapy treatment. These chemotherapy-related side effects can negatively impact patients' quality of life and diet. The aim of this research is therefore to propose a solution to alleviate these taste and smell disorders. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- What is being tested?
- experimental in day hospital and taste and smell disorders questionnaire
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 104 participants
- Where
- 1 siteFrance
- Study dates
- 16 Aug 2022to 30 Jul 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- cancer treated with chemotherapy
- patient with taste and/or smell disorders
Who cannot join
- patient at the end of chemotherapy treatment
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Médipôle Hôpital Mututaliste
Villeurbanne, 69100
laetitia paradisi, +33481655296, l.paradisi-prieur@resamut.fr
About this study
Changes in taste and smell can occur during chemotherapy treatment. These chemotherapy-related side effects can negatively impact patients' quality of life and diet.
The aim of this research is therefore to propose a solution to alleviate these taste and smell disorders. Based on the same principle as rehabilitation proposed for anosmia (loss of smell) related to COVID-19, we hypothesize that olfactory rehabilitation (using the sense of smell) through the odorous properties of essential oils could be effective for chemotherapy-related taste and smell alterations.
- Conditions
- Cancer
- Being tested
- experimental in day hospital, taste and smell disorders questionnaire
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
experimental in day hospitalOther
multidisciplinary day hospital
taste and smell disorders questionnaireOther
Answer to the home-made questionnaire at inclusion and at 6 months
| Study group | Role | What they receive |
|---|---|---|
| Control | Other | no taste and smell rehabilitation Receives: Other: taste and smell disorders questionnaire |
| experimental with day hospital | Experimental | During the day hospital, patients will be made aware of the various taste and smell disorders by the medical and paramedical team (doctor, dietician-nutritionist, speech therapist, therapeutic education nurse) Receives: Other: experimental in day hospital; Other: taste and smell disorders questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
difference in scores between 6 months and the inclusion at "taste and smell disorders" questionnaire
taste and smell disorders home-made questionnaire (score from 0 to 100)
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jun 2025
- Study start16 Aug 2022
- Primary completion30 Dec 2026 (estimated)
- Study completion30 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 104 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Médipôle Lyon-Villeurbanne
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07041710
- Sponsor's protocol ID
- AGORA
- Acronym
- AGORA
- Status last verified
- Oct 2026
- First submitted
- 4 Jun 2025
- Last updated
- 9 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Rehabilitation of Taste and Smell Disorders Associated With Chemotherapy Using Aromatherapy
- ClinicalTrials.gov ID
- NCT07041710
- Acronym / sponsor ID
- AGORA / AGORA
- Conditions
- Cancer
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 104 participants (estimated)
- Lead sponsor
- Médipôle Lyon-VilleurbanneUniversity, hospital or other
- Study start
- 16 Aug 2022 (actual)
- Primary completion
- 30 Dec 2026 (estimated)
- Study completion
- 30 Jul 2027 (estimated)
- First posted
- 27 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Changes in taste and smell can occur during chemotherapy treatment. These chemotherapy-related side effects can negatively impact patients' quality of life and diet.
The aim of this research is therefore to propose a solution to alleviate these taste and smell disorders. Based on the same principle as rehabilitation proposed for anosmia (loss of smell) related to COVID-19, we hypothesize that olfactory rehabilitation (using the sense of smell) through the odorous properties of essential oils could be effective for chemotherapy-related taste and smell alterations.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control | Other | Other: taste and smell disorders questionnaireno taste and smell rehabilitation |
| experimental with day hospital | Experimental | Other: experimental in day hospital, Other: taste and smell disorders questionnaireDuring the day hospital, patients will be made aware of the various taste and smell disorders by the medical and paramedical team (doctor, dietician-nutritionist, speech therapist, therapeutic education nurse) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- cancer treated with chemotherapy
- patient with taste and/or smell disorders
Key exclusion criteria (1 listed)
- patient at the end of chemotherapy treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| experimental in day hospitalmultidisciplinary day hospital | Other | experimental with day hospital |
| taste and smell disorders questionnaireAnswer to the home-made questionnaire at inclusion and at 6 months | Other | Control, experimental with day hospital |
Primary outcome
difference in scores between 6 months and the inclusion at "taste and smell disorders" questionnaire
Time frame: 6 months
taste and smell disorders home-made questionnaire (score from 0 to 100)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing experimental in day hospital and taste and smell disorders questionnaire in people with Cancer, run by Médipôle Lyon-Villeurbanne at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
difference in scores between 6 months and the inclusion at "taste and smell disorders" questionnaire (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2026; AzTrials last refreshed its copy on 8 Nov 2026.